Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-DKS1 CAR-NK cell therapy in relapsed/refractory autoimmune diseases
NCT07095075Phase 1Recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LUCAR-DKS1 in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic sclerosis (SSc) and 2 more (5 arms), sponsored by Legend Biotech Corporation. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Dose-Limiting Toxicity at 2 years and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
LUCAR-DKS1
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07095075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095075.